Stifel Nicolaus Has Lowered Expectations for Artivion (NYSE:AORT) Stock Price

Artivion (NYSE:AORT) had its target price decreased by stock analysts at Stifel Nicolaus from $33.00 to $30.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 17.92% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. JMP Securities reissued a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Needham & Company LLC lowered their price target on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Oppenheimer raised their price target on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $31.40.

Artivion Price Performance

NYSE:AORT opened at $25.44 on Tuesday. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -1,272.00 and a beta of 1.75. Artivion has a 52-week low of $18.38 and a 52-week high of $32.33. The stock has a fifty day moving average of $29.68 and a 200 day moving average of $27.83. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). The business had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. On average, research analysts expect that Artivion will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In other news, CFO Lance A. Berry sold 3,259 shares of Artivion stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $89,003.29. Following the transaction, the chief financial officer now owns 75,805 shares in the company, valued at approximately $2,070,234.55. The trade was a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the transaction, the vice president now owns 33,503 shares in the company, valued at approximately $1,005,090. This represents a 18.53 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 77,224 shares of company stock worth $2,162,330 over the last 90 days. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Quarry LP grew its stake in shares of Artivion by 210.8% in the third quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after purchasing an additional 820 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the last quarter. R Squared Ltd bought a new stake in shares of Artivion in the fourth quarter worth about $39,000. Arcadia Investment Management Corp MI bought a new stake in shares of Artivion in the fourth quarter worth about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Artivion in the fourth quarter worth about $64,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.